Pharmaceutical intervention for treating an apraxia of speech in children
US9375421B2 · kind B2 · utility
0Cited by
4References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 15, 2015 |
| Grant date | Jun 28, 2016 |
| Priority date | — |
| Expiry date | Dec 15, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K31/5375
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A pharmaceutical intervention and therapeutic method for treating an apraxia of speech in children. The child can also be diagnosed with gait abnormalities or impairment autism, mental retardation and dyslexia. If the child demonstrates at least an 18 to 24 month development stage of either verbal development or non-verbal development, a therapeutic dose of a dopamine agonistic, particularly a nonlinear lower alkyl phenidate or dextro-threo-methylphenidate is administered to the child.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.